A Study to Evaluate the Use of Placenta Protein 13 (PP13) in the First Trimester of Pregnancy as a Diagnostic Aiding Tool in the Assessment of the Risk for Developing Preeclampsia in Women With Low and Unknown Risk

This study is currently recruiting participants.

Verified March 2011 by University of Kansas

First Received on December 11, 2007. Last Updated on March 23, 2011 History of Changes

Sponsor:	University of Kansas
Collaborator:	Diagnostic Technologies Ltd.
Information provided by:	University of Kansas
ClinicalTrials.gov Identifier:	NCT00572793

Purpose

The purpose of this study is to evaluate whether it is possible to detect changes in the concentration of PP13 in the blood of pregnant women who may go on to develop the complication of preeclampsia later on in the pregnancy, and if these changes can be detected early enough to allow early diagnosis and treatment for prevention of these complications and reduce their damage. This study will test if the PP13 biomarker during the first trimester of pregnancy has the ability to provide assessment of risk for the development of preeclampsia that necessitates delivery before 37 weeks gestation or can predict preeclampsia before 34 weeks gestation.

Condition
Preeclampsia

Study Type:	Observational
Study Design:	Observational Model: Case Control Time Perspective: Prospective
Official Title:	A Nested Case-Controlled Study Evaluating the Utility of Placental Protein 13 (PP13) In-vitro Diagnostic Kit as a Diagnostic Aiding Tool in Assessment of the Risk for Developing Preeclampsia Necessitating Delivery Before 37 Weeks (Early-preeclampsia) Based on First Trimester Blood Testing of Pregnant Women With Low and Unknown Risk

Further study details as provided by University of Kansas:

Primary Outcome Measures:

Preeclampsia necessitating delivery at gestational age < 37 weeks including HELLP syndrome and eclampsia [ Time Frame: 37 Weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Maternal and Neonatal morbidity and mortality and very early preeclampsia necessitating delivery before 34 weeks [ Time Frame: 34 Weeks, At Delivery ] [ Designated as safety issue: No ]

Biospecimen Retention: Samples Without DNA

Maternal serum - placental protein 13 level

Estimated Enrollment:	2000
Study Start Date:	November 2007
Estimated Study Completion Date:	November 2012

Detailed Description:

After obtaining informed consent maternal demographics, vital signs, height, weight, medical history, pregnancy dating, dipstick for urine protein, previous lab results, nuchal translucency results and uterine artery Doppler results (if done) will be obtained. Blood for PP13 will be obtained at 7-13 weeks and optionally at 21-23 weeks. Hospitalization and delivery information will be obtained via a chart review for evidence of preeclampsia.

Eligibility

Ages Eligible for Study:	16 Years to 45 Years
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	Yes
Sampling Method:	Non-Probability Sample

Study Population

Pregnant patients seen or referred to the obstetrical clinic

Criteria

Inclusion Criteria:

Healthy, pregnant females
Singleton fetus at 7 0/7 to 13 6/7 weeks gestation

Exclusion Criteria:

Multi-fetal pregnancy
Mental retardation
Known fetal anomaly or demise
BMI > 35, serious medical condition

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00572793

Contacts

Contact: Dorinda Sutton, RN CCRC

(913) 588-6287

dsutton@kumc.edu

Locations

United States, Kansas
University of Kansas Medical Center	Recruiting
Kansas City, Kansas, United States, 66160
Contact: Dorinda Sutton, RN 913-588-6287 dsutton@kumc.edu
Principal Investigator: Carl Weiner, MD, MBA

Sponsors and Collaborators

University of Kansas

Diagnostic Technologies Ltd.

Investigators

Principal Investigator:

Carl Weiner, MD, MBA

University of Kansas

More Information

No publications provided

Responsible Party:	Carl Weiner, MD, MBA, University of Kansas Medical Center
ClinicalTrials.gov Identifier:	NCT00572793 History of Changes
Other Study ID Numbers:	11063, 11063
Study First Received:	December 11, 2007
Last Updated:	March 23, 2011
Health Authority:	United States: Institutional Review Board

Additional relevant MeSH terms:

Pre-Eclampsia
Hypertension, Pregnancy-Induced
Pregnancy Complications

ClinicalTrials.gov processed this record on February 09, 2012